SITE007-0033

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2022-03-25

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-12 (study day 3); relationship: N; serious criteria: hospitalization

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-14 (study day 5); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-04-26 (study day 17); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-04-26 (study day 17); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-29 (study day 20); relationship: Y

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-05-01 (study day 22); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-04 (study day 25); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-05-06 (study day 27); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-09 (study day 30); relationship: not assessed

Data queries

No data queries.